Expands entry to vertebrogenic ache therapy for 36 million sufferers
MINNEAPOLIS, Oct. 03, 2023 (GLOBE NEWSWIRE) — Relievant Medsystems, an organization devoted to reworking the analysis and therapy of vertebrogenic low again ache, in the present day introduced that Anthem Blue Cross and Blue Defend has established favorable protection for the Intracept® Process. The protection went into impact on Wednesday, September 27, and expands entry to the process, when clinically acceptable, to greater than 36 million sufferers.
The favorable protection coverage from Anthem Blue Cross Blue Defend is the most recent in a collection of current optimistic protection determinations for the Intracept Process. This consists of protection from Cigna Healthcare, which went into impact in June of 2023 and expanded entry to greater than 19 million lives.
“We proceed to teach payers on the strong scientific proof supporting the efficacy, security and sturdiness of the Intracept Process. The choice from Anthem Blue Cross and Blue Defend is a vital step in increasing affected person and doctor entry to this confirmed therapy,” mentioned Tyler Binney, President and CEO of Relievant Medsystems. “We stay up for constructing on this momentum with the final word purpose of serving to the tens of millions of sufferers with vertebrogenic ache obtain important and sturdy aid.”
Greater than 15,000 sufferers have been handled with Relievant Medsystems’ minimally invasive Intracept Process, the one FDA-cleared therapy for persistent vertebrogenic low again ache. It’s a same-day, outpatient process that makes use of focused radiofrequency power to cease the basivertebral nerve (BVN) from transmitting ache indicators to the mind and takes roughly one hour to carry out.
Based mostly on current information, sufferers usually expertise minimal post-procedure discomfort and a fast restoration. The Intracept Process is supported by robust scientific proof, together with two Stage I randomized scientific trials and information exhibiting enhancements are sustained greater than 5 years post-procedure.
“The scientific efficacy of the Intracept Process is effectively established, and I’ve seen the life-changing ache aid it has given my sufferers. The flexibility to offer a exact, minimally invasive and sturdy therapy for our commonest, but most troublesome, affected person inhabitants is really revolutionary,” mentioned Kevin Macadaeg, MD, Founder and Vice President, Indiana Backbone Group. “This optimistic protection willpower from Anthem Blue Cross and Blue Defend is welcome information to develop affected person entry additional and empower physicians to diagnose and deal with this usually debilitating situation.”
Of the 30 million folks within the U.S. with persistent low again ache, 1 in 6 are more likely to have vertebrogenic ache, a definite kind of persistent low again ache attributable to injury to vertebral endplates, the interface between the disc and the vertebral physique. Sufferers usually have ache in the course of their low again, which worsens after they bend over, sit for lengthy durations of time, or when they’re lively. A doctor can affirm a affected person’s ache is vertebrogenic by observing Modic modifications, a biomarker seen on customary MRI that signifies irritation on the vertebral endplate.
For extra details about the Intracept Process, go to: https://www.relievant.com/intracept/.
About Relievant Medsystems
Relievant Medsystems is a commercial-stage medical machine firm reworking the analysis and therapy of vertebrogenic ache, a type of Continual Low Again Ache (CLBP), with the Intracept Process – a novel, clinically confirmed and commercially accessible therapy designed to enhance the standard of life for tens of millions of indicated sufferers. For extra details about Relievant Medsystems and the Intracept Process, go to www.relievant.com.
Shelli Lissick, Bellmont Companions
(651) 276-6922 | email@example.com
Marissa Bych, Gilmartin Group
(805) 305-1244 | firstname.lastname@example.org